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Interactions of current pandemic COVID-19 and pre-existing major health burden Diabetes Mellitus have posed a serious 
global public health crisis. The emergence of COVID-19 as a communicable viral infection along with the presence of non-
communicable diabetes, have transformed the health system into a knife with two sharp ends. Though diabetes worldwide is 
almost 20 times more than COVID-19 positive cases, the severe virulence and pathogenesis coincides with the routine 
treatment and pathogenesis of diabetes making it one of the most serious comorbid factors. The first three deaths due to 
COVID-19 reported in China were diabetes patients. The severity of the association of diabetes with COVID-19 ranges from 
5 to 20%. Type 1 diabetes mellitus and type 2 diabetes mellitus increase the susceptibility to infections and their 
complications. The present study was attempted to review probable interaction between these two global health burdens and 
possible suggestive management to control their detrimental effect. An intensive online search was conducted using two 
databases, PubMed and Google Scholar. Most hypothesized pathways for COVID-19 infection are the ACE2 receptors and 
RAAS system followed by the DPP4 receptor pathway. This review proposes that proper and timely management of the 
COVD-19 patients with diabetes comorbidity might reduce COVID-19 disease burden. 
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Introduction 
‗Health is a state of complete physical, mental and 
social well-being and not merely the absence of 
disease or infirmity‘ as defined by the World Health 
Organisation (WHO) is at present facing a global 
crisis
1
. The global impact of the novel coronavirus 
which is well known as COVID-19 has led to 20 
million confirmed cases and a death toll of 0.6 million 
as reported till 15
th
 August 2020 (WHO)
2
. Thus it has 
rightly been declared as a pandemic by WHO because 
COVID-19 has paralysed not only the global health 
system but also the economic system and affected 
health in all aspects of physical, mental and social well-
being. There are triple burdens of diseases namely 1) 
Communicable, 2) Non-communicable and 3) Emerging 
infectious. Among the non-communicable diseases 
(NCDs), cardiovascular diseases account for most NCD 
deaths (17.9 million people annually), followed by 
cancers (9.0 million), respiratory diseases (3.9 million), 
and diabetes (1.6 million)
3
. Almost over 80% of all 




The global prevalence of diabetes mainly type 2 
diabetes is 463 million adults (20-79 years).
4
 The 
prevalence of diabetes has been steadily increasing for 
the past 3 decades and most rapidly in low- and middle-
income countries and the count is expected to cross 700 
million by 2045
4
. The advent of COVID-19 as a 
communicable emerging infection along with the 
presence of non-communicable diabetes, have 
transformed the health system into a knife with two 
sharp ends. The high global prevalence of diabetes 
makes it a potential comorbid factor in patients  
with COVID-19 associated disease. Several effects 
especially the impaired immune response, heightened 
inflammatory response and hypercoagulable state have 
contributed to the disease severity
5,6
. It has been 
observed that the severe cases of COVID-19 can rapidly 
progress to Acute Respiratory Distress Syndrome 
(ARDS), septic shock and multiple organ dysfunction 
syndrome (MODS)
7,8
. The association of diabetes  
with COVID-19 was first reported in Chinese studies 





relating to the impact of COVID-19 in people  
with preexisting diabetes is limited but continuing to 
emerge
10
. There is a bidirectional relationship between 








associated with an increased risk of severe COVID-19. 
On the other hand, new onset diabetes and severe 
metabolic complications of preexisting diabetes, 
including diabetic ketoacidosis and hyperosmolarity  
for which exceptionally high doses of insulin are 
warranted, have been reported in patients with  
COVID-19
11
. Although the overall mortality rate of 
COVID-19 is low as 1.4 to 2.3% with certain countries, 
ethnicities demonstrating lower death rates but  
patients with comorbidities are more likely to have 
severe disease symptoms and subsequent higher 
mortality
7
. Both type 1 diabetes mellitus (T1DM) and 
type 2 diabetes mellitus (T2DM) increase the 
susceptibility to infections and their complications
12
. 
Viral infections have been widely associated with 
T1DM pathogenesis which is an autoimmune disease 
characterized by progressive pancreatic β-cells 
destruction and insulin deficiency
13
. T2DM or the adult 
diabetes is among the leading causes of kidney failure 
along with other along with other issues like 
cardiovascular problems, retinopathy and neuropathy 




The COVID-19 pandemic is far from being solely a 
medical phenomenon. It has greatly impacted personal 
and professional lives. To contain the rapid transmission 
of the disease, precautionary steps like isolation, social 
distancing and lockdown have been imposed by the 
government; have significant effect on the health and 
lifestyle of an individual. Management of chronic 
diseases such as diabetes which requires dietary 
modification, regular exercise, good adherence to 
medications and routine medical assistance poses many 
complex challenges
12
. Therefore the present study 
attempted to review studies related to the relation of the 
two global pandemics – Diabetes and COVID-19 and 
possible suggestive management to control the 







An intensive online search was conducted using two 
databases, PubMed and Google Scholar. ―Diabetes‖, 
―COVID-19‖ and ―Sars-CoV-2‖ keywords were mainly 
used for the search with the interposition of the Boolean 
Operator ―AND‖. COVID-19 AND Diabetes, Diabetes 
AND Sars-CoV-2, were used in PubMed and Google 
Scholar to retrieve relevant articles. Published articles 
were accounted for through the period of March 2020 to 
August 2020. Furthermore, the renowned international 
organizations were also included in the search, to 
establish the current information pertaining to diabetes 
population and coronavirus transmission. The 
international organizations were: World Health 




Full-length scientific research articles, letters to the 
editor, commentaries and review articles like systematic 
reviews, meta-analysis and mini reviews in the English 
language have been included. Research articles on 
Randomized Controlled Trials (RCTs) on both sexes 
(male and female) were considered to get clear view of 
the hypothetical pathophysiology of COVID-19 
infection. Studies showing patients of any age group 
suffering from COVID-19 infection with or without 
diabetes mellitus as the only comorbid factor were 
considered. 
 
Diabetes mellitus and coronavirus 
The Diabetes Mellitus (DM) represents a group of 
diseases of heterogeneous etiology, mostly characterized 
by chronic hyperglycemia and other metabolic 
abnormalities
16
. Type 2 diabetes or T2DM occurs when 
the body becomes resistant to insulin or doesn't make 
enough insulin and is one of the serious devastating 
diseases found in enormous proportions
17
. Type 1 
diabetes or T1DM is characterized by auto-immune 
destruction of insulin-producing pancreatic β-cells and 
systemic derangements. A steady rise in the incidence of 
T1DM is happening globally
18
. In December 2019, an 
unknown respiratory infection which was fatal in certain 
cases was reported from Wuhan, China. Later a new 





March WHO declared it as a pandemic
20
. According to 
the World Health Organisation (WHO) some of the 
lethal coronavirus varieties, found to affect global public 
health are SARS-CoV (Severe Acute Respiratory 
Syndrome coronavirus) in 2002; MERS-CoV (Middle 
East Respiratory Syndrome coronavirus) in 2012 and the 
newly emerged novel coronavirus also known as SARS-
CoV-2 in 2019, which was renamed as COVID-19 in 
2020
2,19
. Coronavirus is made up of four structural 
proteins: spike (S), membrane (M), nucleocapsid (N), 
and envelope (E) proteins. Like other coronaviruses, 
SARS-CoV-2 or COVID-19 particles are spherical and 
have proteins called spikes protruding from their 
surface
21,22
. The S protein mediates receptor binding on 
the host cell membrane through the receptor-binding 
domain (RBD) in the S1 domain and membrane fusion 
through the S2 subunit
22
. The structure of the outer 




covering made of proteins and polypeptides are easily 
digestible by alcohol based products
23,24
. Although the 
disease supposedly originated from a zoonotic virus 
transmission by live wild animals, it became a person-
to-person transmitted infection: the virus is mostly 
carried by asymptomatic or mild symptomatic people
13
. 
COVID-19 and diabetes represent two devastating 
pandemics with very different characteristics in terms of 
healthcare burden mainly because of different 
presentation (acute vs chronic) and transmission 
(communicable vs noncommunicable), but which may 
be much closer than previously thought
25
 (Fig. 1 & 2). 
 
Prevalence of diabetes mellitus and COVID-19 
According to WHO, the global impact of the novel 
coronavirus which is well known as Sars-Cov-2 or novel 
coronavirus has led to 20966523 confirmed cases and a 





Whereas, the global prevalence of diabetes is 463 million 
adults (20-79 years) and almost 1.1 million children and 
adolescents with total 4.2 million deaths according to the 
International Diabetes Federation (IDF)
4
. The following 
graphical representation (Fig. 3) shows the worldwide 
spread of the novel coronavirus disease and its 
comparison with the global prevalence of diabetes 
(T2DM mainly). The following table represents  
the global COVID-19 cases and deaths in comparison 
with global diabetes cases and deaths due to diabetes 
(Table 1). 
Pathogenesis of COVID-19 
Various mechanisms have been suggested for 
probable entry and cause of infection of COVID-19 in 
human cells. Most pathways are detrimental to diabetics 
as it can aggravate the infection causing higher 
susceptibility and mortality rate. Figure 4 shows the 
graphical representation of various hypothesis given in 
literature that supports the pathogenesis of COVID-19. 
It is seen that the most supported mechanism of 
infection of COVID-19 is through the Angiotensin 
Converting Enzyme 2 (ACE2) receptor. More clinical 
evidence and research is warranted to validate this 
pathway of infection. It may be hypothetized that the 
aerosolized uptake of SARS-CoV-2 or COVID-19 
virus invasion into the respiratory epithelium and 
other target cells involves its binding to cell surface 
angiotensin converting enzyme 2 (ACE2) receptors. 
Increased expression of ACE2 may favor more 
efficient cell binding and entry into cells. Early 
recruitment and function of neutrophils and 
macrophages are impaired in Diabetes Mellitus (DM). 
Delay in the initiation of adaptive immunity and 
dysregulation of the cytokine response in DM may 





Fig. 1 — Transmission electron microscope image shows SARS-
CoV-2, the virus that causes COVID-19, isolated from a patient in the 
U.S. Virus particles are emerging from the surface of cells cultured in 
the lab. The spikes on the outer edge of the virus particles give 
coronaviruses their name, crown like. NIAID-RML21 
 
 
Fig. 2 — Atomic-level structure of the SARS-CoV-2 spike protein. 
The receptor binding domain, the part of the spike that binds to the 
host cell, is colored green. UT Austin, McLellan Lab21 





In empirical hospital based studies it has been 
found that around 20% of diabetics suffering from a 
virus are at risk of developing severe pneumonia
26
. 
Epidemiological observations from regions heavily 
affected by COVID-19 along with reports from the 
Centers for Disease Control and Prevention (CDC) 
and other national health centres and hospitals showed 
that the risk of a fatal outcome from this virus is up to 
50% higher in patients with diabetes than in those 
who do not have diabetes
26
. 
In the literature it can be seen that there are various 
preferable pathways that contribute to the entry of 
COVID-19 virus into the human cells and infect them. 
The most widely accepted theory is the use of 
Angiotensin Converting Enzyme 2 (ACE2) receptors for 
entry into the cells. ACE2 is a type 1 integral membrane 
glycoprotein that is constitutively expressed by the 
epithelial cells of the key metabolic organs and tissues, 
including pancreatic beta cells, adipose tissue, small 
intestine, kidneys, lungs, and blood vessels
5,7,11
. In 
normal physiology, ACE2 plays an important role in 
anti-inflammation and anti-oxidation. It is responsible 
for the degradation of angiotensin-II as well as 
angiotensin-I (to a lesser extent) to smaller peptides, 
namely angiotensin (1–7) and angiotensin (1–9), 
respectively
7,27
. The former peptide (angiotensin 1–7) is 
responsible for the anti-inflammatory and antioxidant 
role. This process is compromised as part of the diabetes 
pathophysiology
27
. ACE2 expression is reduced in 
patients with DM possibly due to glycosylation; this 
might explain the increased predisposition to severe lung 
injury and ARDS with COVID-19
7
. The expression of 
ACE2 is substantially increased in patients with T1DM 
or T2DM by medication
28
. The ACE2 receptor may be 
increased using specific medications, like Glucagon like 
peptide-1 (GLP-1) agonists, thiazolidinediones, ACE 
inhibitors (ACEi), statins, and angiotensin-II type-1 
receptor blockers (ARBs), all of which are frequently 
given to individuals with diabetes
29
. Diabetes treatment 
with ACE2-stimulating drugs increases the risk of 
developing severe and fatal COVID-19
28
. Insulin is the 
preferred agent for control of hyperglycemia in 
hospitalized sick patients
30
. As an adaptive response to 
counteract the elevated levels of angiotensin-II, 
expression of ACE2 is increased. First, to gain entry to 
its target cells, the novel coronavirus hijacks an 
endocrine pathway that plays a crucial role in regulation 
of blood pressure, metabolism, and inflammation. ACE2 
receptors on the host pneumocytes (lung cells) are used 
by the spike proteins for entry. ACE2 upregulation 
facilitates the entry and subsequent proliferation of the 
coronavirus
31
. ACE2 has protective effects primarily 
regarding inflammation. COVID-19 infection reduces 
ACE2 expression inducing cellular damage, hyper 
inflammation, and respiratory failure
26
. Once the virus 





Adults with Diabetes  
(20-79 years) 
Diabetes related death  
(20-79 years) 
India 2526192 49036 77005600 1010262 
China 89695 4708 116446900 823780 
Russian Federation 917884 15617 8288500 110530 
Japan 53577 1085 7390500 71513 
France 198876 30275 3480000 18656 
Spain 342813 28617 3619100 15394 
Italy 252809 35234 3669400 15656 
UK 316371 41357 2680500 13951 
USA 5203206 165995 30987900 188969 
Brazil 3224876 105463 16780800 135197 
Australia 22743 375 1288300 5175 
New Zealand 1258 22 259800 1069 
 
 
Fig. 3 — COVID-19 and Diabetes situation in different WHO 
region 




uses the enzyme to gain entry into the host tissue, ACE2 
gets downregulated and it is unable to protect against 
lung injury
30
. Early coronavirus family i.e. SARS-CoV 
bind to ACE2 in pancreatic islet cells, damage them  
and cause acute hyperglycemia, possibly contributing  
to an excessive mortality rate, even among people 




A second potential mechanism that might explain 
the link between COVID-19 and diabetes involves the 
dipeptidyl peptidase-4 (DPP-4) enzyme, which is 
commonly targeted pharmacologically in people  
with type 2 diabetes. In cell studies, DPP-4 was 
identified as a functional receptor for human 
coronavirus-Erasmus Medical Center (hCoV-EMC), 
the virus responsible for MERS. Antibodies directed 
against DPP-4 inhibited hCoV-EMC infection of 
primary cells. DPP-4 enzyme is a ubiquitously 
expressed type II transmembrane glycoprotein. It 
plays a major role in glucose and insulin metabolism 
but also increases inflammation in T2DM
26
. Similar 
evidence of risk among persons with diabetes has 
been reported for the two earlier coronavirus 
infections, severe acute respiratory syndrome (SARS) 
beginning in 2002 and affecting more than 8000 
persons, mainly in Asia and the Middle East known as 
Middle East Respiratory Syndrome (MERS) in 2012 
affecting more than 2000 persons, mainly in Saudi 
Arabia. As MERS-CoV binds to the receptor-binding 
domain of human dipeptidyl peptidase IV (DPP-IV), a 
transgenic mouse model expressing this DPP-IV 
receptor on pulmonary alveolar cells has been used to 
study the effect of diabetes in worsening disease 
severity, showing an association of diabetes with 
greater weight loss and greater pulmonary 
inflammation, with infiltration of macrophages
32
. So 
novel coronavirus maybe assumed to follow this 
pathway as well. 
People with diabetes are more susceptible to an 
inflammatory cytokine storm eventually leading to 
ARDS, shock and rapid deterioration due to COVID-
19
31
. Interleukin-6 (IL-6), which is already increased in 
conditions of chronic inflammation, may play a more 
deleterious role in COVID-19 infection
25
. IL-6 is a 
pleiotropic cytokine that mainly participates in acute 
phase inflammatory responses, but is seen to significantly 
increase in conditions of chronic inflammation such as 
metabolic disorders and cardiovascular diseases
25
. 
Targeting the over expression of IL-6 effects with a 
monoclonal antibody against IL-6 receptor or using Janus 
Kinase inhibitors may be particularly helpful for 
treatment of COVID-19 pneumonia in diabetics
25
. 
Interleukin-6, amongst the different markers of 
inflammation (fibrinogen, C-reactive protein, D-dimer) 
that were found to be more elevated in COVID-19 cases 
with diabetes than in those without, deserves particular 
attention
25
. In a study it was found that, serum levels of 
inflammation-related biomarkers IL-6, C-reactive 
protein, serum ferritin and coagulation index, D-dimer, 
were significantly higher (P <0.01) in diabetic patients 
compared with those without, suggesting that patients 
with diabetes are more susceptible to an inflammatory 
storm eventually leading to rapid deterioration due to 
COVID-19
33
. Even mild COVID-19 can induce a pro-
inflammatory milieu, as evident by high amounts of IL-6, 
IL-1β, tumor-necrosis factor α (TNF-α), monocyte 
chemoattractant protein-1 (MCP-1) and inducible 
protein-10 that can further lead to lowering of insulin 
sensitivity
31
. COVID-19 patients with DM had higher D-
dimer levels than those without DM; perhaps signifying 
over-activation of the hemostatic system. Amid an 
already underlying pro-thrombotic hypercoagulable state 
predisposed by the mere presence of DM, over-activation 
of the coagulation cascade in COVID-19 can lead to fatal 
thrombo-embolic complications and eventual mortality
31
. 
Non-structural proteins of SARS-CoV-2 attacks the β-1 
chain of hemoglobin leading to dissociation of iron from 
porphyrin, thereby impairing the ability of hemoglobin to 
carry oxygen. COVID-19 virus may have a higher 
affinity to bind to glycated hemoglobin than non-glycated 
hemoglobin, thus making it more prone to diabetics as 




For patients with type 1 diabetes, monitoring of ketone 
levels (particularly for people who are persistently 
hyperglycaemic) and vigilance for the development of 
symptoms of Diabetic Ketoacidosis (DKA) are 
important. DKA occurs as a result of insulin deficiency 
 
 
Fig. 4 — Probable mechanism of COVID-19 pathogenesis 




and increased counter regulatory responses, which favour 
the production of ketones. For type 1 diabetics with 
COVID-19 and hyperglycaemia, it is important to 
monitor their blood glucose and ketone levels also 
maintain hydration and continue insulin therapy
12
. The 
interactions between COVID-19 and the renin 
angiotensin-aldosterone system (RAAS) might provide 
another mechanism in the pathophysiology of DKA
34
. In 
addition, the relationship between COVID-19 and the 
RAAS can complicate DKA management. Excessive 
fluid resuscitation may potentiate ARDS as angiotensin-
II increases pulmonary vascular permeability and 
worsens damage to lung parenchyma. Furthermore, 
angiotensin-II stimulates aldosterone secretion, 
potentiating the risk of hypokalemia, which may 
necessitate more potassium supplementation in order to 
continue intravenous insulin to suppress ketogenesis
34
. 
Hypokalemia, in turn, can worsen glucose control in 
patients with T1DM and T2DM
31
. Thus, educating and 
making T1DM patients aware of this complication and 
about typical symptoms, if possible home-measurement 
of urine or blood ketones, acute behavioral guidelines, 
and timely professional medical advice is crucial, 
although it might be difficult in low and middle  
income countries
26
. Frequent changes in dosage and 
correctional bolus may be required to maintain 
normoglycemia
30
. Early reports indicate that among 
patients with pre-existing diabetes, DKA may be a 




It is not just diabetes that is making COVID-19 more 
deadly; it is also possible that COVID-19 is making 
diabetes worse
29
. It is plausible that SARS-CoV-2 may 
cause pleiotropic alterations of glucose metabolism that 
could complicate the pathophysiology of preexisting 
diabetes or lead to new mechanisms of the disease
11
. 
Pancreatic damage from the virus and resultant 
impairment in -cell, insulin secretion could worsen 
preexisting diabetes or even predispose to new cases of 
diabetes in non-diabetic subjects. This could make 
hyperglycemia worse in the short term and thus lead to a 
more severe COVID-19 disease course triggering the 
emergence of increased rates of autoimmune diabetes, 
whereby the body coordinates an immune response to the 




Neutrophil dysfunction, reduced T cell response and 
disordered humoral immunity are contributory, and 
bacterial and viral respiratory tract infections are 
particularly common phenomena
12
. Preexisting diabetes 
is significantly associated with greater risk of severe or 
critical illness and in-hospital mortality in patients 
admitted to hospital with COVID-19 infection
39
. The 
histological and pathological changes in the pancreatic 
β-cells also pose a risk of developing new type of 
diabetes after COVID-19 virus infection. 
Based on the evidences obtained from clinical 
studies and literature, it is evident that COVID-19 
virus infection and its pathophysiology coincides with 
diabetes pathogenesis. So timely management, proper 
dissemination of facts and knowledge along with the 
adoption of variation in treatment strategy based on 
severity of COVID-19 infection and duration of 
diabetes is necessary. 
Antioxidants and vitamins are hypothesized to play a 
protective role in COVID-19 infection and also prevent 
virus infection. Vitamin C supplementation has some 
role in prevention of pneumonia and its effect on 
COVID-19 needs further research and validation
30
. 
Vitamin D deficiency can lead to worsening of glucose 





Recent management strategies adopted 
Management of patients with diabetes in times of 
restrictions on mobility poses some challenges and 
novel approaches like telehealth or telemedicine or 
telesensitization can be useful
5
. Alternative approaches 
to manage people with diabetes with greater urgency 
and efficiency is the need of the hour. Patients with 
new-onset type 1 diabetes represent one of the more 
challenging health conditions. In a study by Garg et. al. 
(2020) two case reports were presented of an adult 
patient (20 years old) and a child (12 months of age) 
where telemedicine was effectively used during 
COVID-19 pandemic at Colorado, USA
36
. This case 
study helped to provide perspectives regarding the 
future applications of tele-diabetes
36
. Hopefully, 
telehealth and digital diabetes care will better enable 
health-care providers to reach the millions of people 
with either type 1 or type 2 diabetes who currently do 
not achieve the desired level of glycemic control, 
thereby improving quality of care and reducing societal 
health-care costs
36
. Due to the ever-increasing global 
prevalence and cost of diabetes associated with 
inadequate availability of healthcare providers and 
access to care, especially in remote places and in 
emerging economies, the majority of the patients 
worldwide will require adequate investments in digital 
health. New diabetes technologies have the promise of 




improving the quality and duration of life, reducing 
costs and complications. Several studies have 
demonstrated the safety, efficacy, and cost 
effectiveness of this technological revolution
36
. To 
achieve further benefits, extensive studies of these 
technologies are required. While many of the 
technological opportunities are now becoming 
available, an improved understanding of patient 
behaviors and lifestyle choices is needed in order to 
achieve the full potential for emerging digital health 
technologies for patients especially with diabetes
36
. 
Telehealth as defined by WHO, is the ‗delivery of 
health care services, where patients and providers are 
separated by distance. Telehealth uses Information and 
Communication Technology (ICT) for the exchange of 
information for the diagnosis and treatment of diseases 
and injuries, research and evaluation, and for the 
continuing education of health professionals. Telehealth 
can contribute to achieving universal health coverage by 
improving access for patients to quality, cost-effective 
and proper health services wherever they may be. It is 
particularly valuable for those in remote areas, 
vulnerable groups and ageing populations
37
. People with 
diabetes are at risk even if not contracted with  
COVID-19. The healthcare setting due to COVID-19 
lockdown and restrictions imposed like social distancing 
and isolation have posed problems for diabetics for 
regular health checkups and lifestyle modifications, like 
exercise and diet. Online mode of support, monitoring 
by health care professionals and consistent sensitization 
is important. Table 2 summarizes few attempts taken by 
countries who were worst affected by COVID-19, to 
help and support diabetics
10
.  
Online initiatives (like some mentioned in the 
Table 2) must be taken into consideration and more 
surveys and researches need to be conducted to assess 
the feasibility and accessibility of these modes of 
health checkups and sensitization programmes to 
contain and maintain diseases like diabetes during 
public health emergencies as posed by COVID-19 
pandemic. More countries in South East Asia and 
other places are making policies to adopt such 
measures to help vulnerable patients specially those 
who do not live in vicinity of healthcare providers. 
 
Conclusion 
People with diabetes comorbidity should be treated 
as a vulnerable group in case of COVID-19 infection
12
. 
T1DM and T2DM both are susceptible to infections 
and their associated complications. Diabetic 
comorbidity might increase the magnitude of the 
COVID-19 severity many fold as compared to non-
diabetics
38
. It is reported that the severity of the 
association of diabetes with COVID-19 ranges from 5 to 
20%. Impaired humoral immunity with cytokine storm is 
a common phenomenon with COVID-19 infection, along 
with autoimmune risk of pancreatic β-cells which may 
pose a risk of developing new type of diabetes after 
COVID-19 virus infection. Maintaining regular health 
checkup and treatment of diabetes patients seem to be a 
matter of great concern in the current lockdown situation 
because of containment of COVID-19 pandemicity. 
Monitoring health conditions of diabetes patients  
through distant monitoring system like teleconsultation 
and telemedicine might play a pivotal role in the 
management of this disease in single and or with 
COVID-19 in combination. Globally, the diabetic 
people are of great concern and sensitive to COVID-19 
infection. Focused interventions are needed to address 
the severity of COVID-19 with diabetic comorbidity.  
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